Geode Capital Management LLC Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Geode Capital Management LLC cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,114,778 shares of the specialty pharmaceutical company’s stock after selling 83 shares during the period. Geode Capital Management LLC owned about 1.84% of Jazz Pharmaceuticals worth $124,227,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after acquiring an additional 704 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Jazz Pharmaceuticals by 24.5% during the 2nd quarter. Blue Trust Inc. now owns 1,307 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 257 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock valued at $816,289 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JAZZ. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $122.49 on Wednesday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The stock has a market cap of $7.41 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The business’s 50 day moving average is $117.72 and its 200-day moving average is $112.36. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.